| Document |
Document Title |
|
WO/2021/252494A1 |
Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composit...
|
|
WO/2021/222858A1 |
Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the tre...
|
|
WO/2021/217092A1 |
A redox flow battery including: a catholyte including a radical dication of a conjugated heterocyclic carbenium compound; and an anolyte including a neutral radical of a conjugated heterocyclic carbenium compound; wherein the conjugated ...
|
|
WO/2021/203811A1 |
The present invention relates to benzothiazinone compounds, a preparation method therefor and an application thereof as an anti-tuberculosis drug, and in particular to compounds having a benzothiazinone skeleton. The compounds are shown ...
|
|
WO/2021/203812A1 |
Disclosed are a benzothiazinone derivative, a preparation method therefor and use thereof as an anti-tuberculosis drug. The present invention specifically relates to a new class of compounds having a benzothiazinone skeleton. Such compou...
|
|
WO/2021/202839A1 |
Provided herein are novel polymorphic forms of metopimazine mesylate. These polymorphic forms are useful in methods, compositions, and kits for the treatment of an enteric nervous system disorder.
|
|
WO/2021/188606A1 |
The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also prov...
|
|
WO/2021/168582A1 |
The present invention generally relates to a chemical process under flow conditions for manufacturing compounds which absorb ultraviolet (UV) radiation and protect biological materials as well as non-biological materials from damaging ex...
|
|
WO/2021/172112A1 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition, represented by specific general formula (1), containing (A) a resin, and (B) a compound that produces an acid when irradiated with actinic...
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
|
WO/2021/171235A1 |
Provided herein is a process for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride: Formula (I). The said process comprises preparing 3,7-dibromophenothiazin-5-ium bromide wet Crude(III) from phenothiazine (II) along pro...
|
|
WO/2021/161838A1 |
Provided is a diarylamine compound represented by general formula (1) below. (A1)m – A2 – (A3 – A4)n (In general formula (1): A1 is a group that is capable of bonding with a hydroxyl group; A2 is an optionally substituted C1–30...
|
|
WO/2021/161230A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2021/144395A1 |
The present invention relates to certain carboxylic dithiocarbamic acid anhydride compounds compounds and their use as photoinitiators in living free-radical polymerization reactions. The invention also relates to curable or cross-linkab...
|
|
WO/2021/122538A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/098715A1 |
A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine co...
|
|
WO/2021/039800A1 |
Provided is an enantiomer preparation method in which one enantiomer of a sulfoxide compound is selectively prepared, the sulfoxide compound having a sulfur atom of a sulfoxide group as an asymmetric center, and the method comprising: a ...
|
|
WO/2021/036851A1 |
The present disclosure relates to the technical field of electronic components, and provided therein are a nitrogen-containing compound represented by formula (I), an organic electroluminescent device and a photoelectric conversion devic...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/012014A1 |
The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase e...
|
|
WO/2020/254697A1 |
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a compo...
|
|
WO/2020/247504A1 |
Provided herein are compounds of formula (I) which comprise a thiomorpholine 1,1-dioxide or 1-imino-thiomorpholine 1-oxide moiety, or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a c...
|
|
WO/2020/233583A1 |
The present invention relates to an isoquinolinone compound, which acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1), and the use thereof, and further relates to a pharmaceutical co...
|
|
WO/2020/237063A1 |
A compound with the following general formula (I) and a general method of making this compound are provided. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are each independently selected from the group that includes H, h...
|
|
WO/2020/227592A1 |
Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates ar...
|
|
WO/2020/222118A1 |
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.
|
|
WO/2020/216777A1 |
The present invention relates to a composition comprising a compound of formula (I) wherein X is selected from the group consisting of S, Se, P, PO, SO, NR1, CR1, CR1R1 or C0-2-alkyl; Z is selected from the group consisting of hydrogen, ...
|
|
WO/2020/211124A1 |
The present invention relates to a thermally activated delayed fluorescence material, a preparation method therefor, and an organic light-emitting diode device. The structural general formula of the thermally activated delayed fluorescen...
|
|
WO/2020/211121A1 |
The present invention relates to a thermally activated delayed fluorescence material, a preparation method therefor, and an organic electroluminescent diode device, the structural general formula of the thermally activated delayed fluore...
|
|
WO/2020/163554A1 |
Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for examp...
|
|
WO/2020/158870A1 |
The purpose in one embodiment of the present invention is to provide a therapeutic for Parkinson's disease, etc. A compound represented by formulas (1), (2), or (8) or a pharmacologically acceptable salt thereof can be used in the treatm...
|
|
WO/2020/145250A1 |
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.
|
|
WO/2020/124771A1 |
The present invention relates to a thermally activated delayed fluorescent compound, a preparation method therefor and an organic electroluminescent diode device thereof. The thermally activated delayed fluorescent compound has a structu...
|
|
WO/2020/117461A1 |
A composition that includes one or more compounds represented by the formula (A): wherein R1 and R2 are same or different and are the residue of an alkyl group having more than 10 carbon atoms wherein the composition has a viscosity (Kvi...
|
|
WO/2020/106642A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
|
|
WO/2020/094542A1 |
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...
|
|
WO/2020/082601A1 |
Disclosed are a dark red photothermally activated delayed fluorescence material, a synthesis method therefor and an electroluminescent device. The dark red photothermally activated delayed fluorescence material is a target compound, whic...
|
|
WO/2020/083327A1 |
Disclosed in the present invention is an organic compound containing a spirobifluorene structure, having a structure as represented by chemical formula (1), wherein Ar1(Ar2)N-(S1)m- and -(S2)n-NAr3(Ar4) are different, and have symmetrica...
|
|
WO/2020/072377A1 |
The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin s...
|
|
WO/2020/020178A1 |
An organic compound as shown in formula (1). Ar 2 has a structural formula as shown in formula (2), and a plurality of Ar 2 may be the same or different. The compound as shown in formula (1) can be used as a luminescent layer material of...
|
|
WO/2020/018929A1 |
In one aspect, the invention provides compounds and methods that are useful for treating bacterial infections.
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2018/226589A9 |
The disclosure is directed to compounds of the formula (I) and (II) and uses of such compounds to treat, among other conditions, neurodegenerative diseases and cancers.
|
|
WO/2019/185882A1 |
The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hy...
|
|
WO/2019/183385A1 |
Provided herein, are compounds, compositions and methods of treatment of cancers using an inhibitor of MAPK/ERK Kinase (MEK), in particular hydrazine derivatives.
|
|
WO/2019/169627A1 |
Disclosed is a thiazine oligomer as a good grinding stabilizer and anticorrosive coating agent for graphene molecular crystals. Also disclosed is a preparation method for the thiazine oligomer, and a graphene grinding dispersion liquid a...
|
|
WO/2019/152536A1 |
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
|
|
WO/2019/129213A1 |
Disclosed are an amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines. The compound or the ph...
|
|
WO/2019/097503A1 |
The present invention relates to the treatment of cancer using combination therapy comprising a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), in combination with an ant...
|
|
WO/2019/085684A1 |
Disclosed in the present invention are a cyanobenzene-containing or thiocyanobenzene-containing compound and applications thereof in organic electroluminescent devices. The compound is formed by cyanobenzene or thiocyanobenzene groups, h...
|
